Hepion Pharmaceuticals, Inc. financial data

Symbol
HEPA on Nasdaq, CTRVP on OTC
Industry
Pharmaceutical Preparations
Location
399 Thornall Street, First Floor, Edison, NJ
State of incorporation
Delaware
Fiscal year end
December 31
Former names
ContraVir Pharmaceuticals, Inc. (to 7/23/2019)
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 391 % -35.9%
Debt-to-equity 88.6 % +253%
Return On Equity -329 % -232%
Return On Assets -174 % -120%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 5.8M shares +51.1%
Common Stock, Shares, Outstanding 5.8M shares +51.1%
Entity Public Float 40.3M USD -7.14%
Common Stock, Value, Issued 547 USD +42.4%
Weighted Average Number of Shares Outstanding, Basic 5.8M shares +51.6%
Weighted Average Number of Shares Outstanding, Diluted 5.8M shares +51.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 23.6M USD -32.3%
General and Administrative Expense 7.93M USD -25.7%
Operating Income (Loss) -34.8M USD +23.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -31.7M USD +30.4%
Income Tax Expense (Benefit) -3.38M USD -17.1%
Net Income (Loss) Attributable to Parent -28.4M USD +33.6%
Earnings Per Share, Basic -6.4 USD/shares +46.8%
Earnings Per Share, Diluted -6.4 USD/shares +46.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current 5.48M USD -83.3%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 151K USD
Goodwill 0 USD -100%
Assets 6.01M USD -83.5%
Accounts Payable, Current 447K USD -89.3%
Employee-related Liabilities, Current 0 USD -100%
Accrued Liabilities, Current 375K USD -87.9%
Liabilities, Current 976K USD -87.3%
Deferred Income Tax Liabilities, Net 0 USD -100%
Operating Lease, Liability, Noncurrent 41.2K USD
Liabilities 2.45M USD -75.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax -53.8K USD +38.6%
Retained Earnings (Accumulated Deficit) -231M USD -14%
Stockholders' Equity Attributable to Parent 3.56M USD -86.5%
Liabilities and Equity 6.01M USD -83.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.62M USD +56%
Net Cash Provided by (Used in) Financing Activities 1.85M USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 120M shares 0%
Common Stock, Shares, Issued 5.8M shares +51.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.68M USD +79.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.12M USD -93.1%
Deferred Tax Assets, Valuation Allowance 44.5M USD +43.2%
Deferred Tax Assets, Gross 44.6M USD +40.8%
Operating Lease, Liability 154K USD
Depreciation 94.4K USD -0.75%
Payments to Acquire Property, Plant, and Equipment 0 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -28.3M USD +33.7%
Lessee, Operating Lease, Liability, to be Paid 167K USD
Operating Lease, Liability, Current 154K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 97.8K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 97.8K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.15 pure +123%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 12.8K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 0 USD
Depreciation, Depletion and Amortization 30.8K USD +70.5%
Deferred Tax Assets, Net of Valuation Allowance 62.5K USD -88.9%
Share-based Payment Arrangement, Expense 1.2M USD -57%
Interest Expense 11.5K USD +11.8%